Physician

Richard Hempstead, MD

According to 2025 Medicare claims, Richard Hempstead, MD (NPI: 1730142191) practices dermatology in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is RICHARD W HEMPSTEAD MD PA (NPI: 1144337676; TIN: 850336577) and primary practice location at 88001-1260.

Hempstead's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 524 traditional Medicare patients, billed 3,213 HCPCS/CPT codes, and received $235,796 in Medicare payments. The top billing code was 17004 (Destruction of precancer skin growth, 15 or more growths). Part D data shows 392 prescription claims across 161 beneficiaries totaling $13,755 in drug costs, led by Fluorouracil (Fluorouracil). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $27,050 and ending at $13,755. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$145K$290K2015 Medicare payment: $248,726 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $243,575 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $219,474 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $232,084 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $278,368 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $249,514 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $288,843 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $275,689 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $290,465 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $235,796 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20157232,979$248,726
20167202,993$243,575
20176742,801$219,474
20187192,989$232,084
20197193,259$278,368
20207062,975$249,514
20216453,261$288,843
20226033,207$275,689
20235623,424$290,465
20245243,213$235,796

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$17K$33K2015 Drug cost: $27,050 (USD; Tot_Drug_Cst)2016 Drug cost: $25,590 (USD; Tot_Drug_Cst)2017 Drug cost: $15,462 (USD; Tot_Drug_Cst)2018 Drug cost: $18,504 (USD; Tot_Drug_Cst)2019 Drug cost: $33,233 (USD; Tot_Drug_Cst)2020 Drug cost: $18,949 (USD; Tot_Drug_Cst)2021 Drug cost: $19,355 (USD; Tot_Drug_Cst)2022 Drug cost: $9,654 (USD; Tot_Drug_Cst)2023 Drug cost: $15,505 (USD; Tot_Drug_Cst)2024 Drug cost: $13,755 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015127291$27,050
2016151316$25,590
2017128274$15,462
2018188399$18,504
2019189480$33,233
2020192502$18,949
2021156462$19,355
2022124354$9,654
2023155435$15,505
2024161392$13,755

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17004Destruction of precancer skin growth, 15 or more growths426700$99
17111Destruction of skin growth, 15 or more growths421663$76
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more260389$74
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more163193$55
88305Pathology examination of tissue using a microscope, intermediate complexity187641$26

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FluorouracilFluorouracil391,140$3,125
CalcipotrieneCalcipotriene25458$3,057
FluocinonideFluocinonide17510$1,357
Clobetasol PropionateClobetasol Propionate17421$880
MupirocinMupirocin64850$782

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Richard Hempstead, MD?

Tedicare shows public-source Medicare data for Richard Hempstead, MD (NPI 1730142191), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Hempstead, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard Hempstead, MD?

Richard Hempstead, MD is linked to RICHARD W HEMPSTEAD MD PA (billing NPI 1144337676) in the available physician profile data.

Does Richard Hempstead, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.